enGene is a public clinical-stage biopharmaceutical company based in Montreal, Canada and Boston, United States. enGene is developing a potential best-in-class gene therapies based on its novel DDX delivery platform. The company's lead program, EG-70, is being studied for the treatment of non-muscle invasive bladder cancer (NMIBC). enGene is listed on the NASDAQ under the ticker ENGN.